• Novozymes’ nine-month 2026 adjusted EBITDA margin rose year over year to 37.9%.
• The acquisition of MicroBioGen’s remaining 77% closed October 1, providing full access to its yeast platform.
• The confirmed 2026 outlook targets 7-8% organic sales growth and adjusted EBITDA margin at the higher end of 37-38%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novozymes A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050158OMX_____CNEWS_EN_GNW1001301928_en) on November 05, 2026, and is solely responsible for the information contained therein.